Benufutamab
Benufutamab (GEN1029) is a death receptor 5 (DR5) -specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1].
Product Specifications
CAS Number
[2109730-69-8]
Product Name Alternative
GEN1029
UNSPSC
12352203
Target
Apoptosis; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/benufutamab.html
Purity
98.62
Solubility
10 mM in DMSO
Smiles
[Benufutamab]
Molecular Weight
(145 kDa)
References & Citations
[1]Hilma J van der Horst, et al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5 (8) :2165-2172. |[2]Marije B Overdijk, et al. Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Mol Cancer Ther. 2020 Oct;19 (10) :2126-2138.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
